54 results about "Opioidergic" patented technology

Methods and compositions are provided for treating individuals exhibiting opioid withdrawal symptoms with opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of opioid withdrawal symptoms, including respiratory depression, sedation, and hypotension. Methods and compositions are also provided for treating stimulant overdose with a benzodiazepine and beta-adrenergic blocking agent. Methods and compositions are also provided for treating concurrent stimulant and opioid overdose comprising administering to a patient in need thereof a benzodiazepine and an opioid antagonist. Methods and compositions are also provided for treating individuals exhibiting opioid withdrawal symptoms or prophy tactically treating individuals for opioid withdrawal symptoms from opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of withdrawal, including respiratory depression, sedation, and hypotension.

A portable emergency response kit designed for rapid intervention in opioid overdose or cardiac arrest scenarios comprises a durable case with compartments for specific medical devices, such as opioid overdose treatment medication or an Automated External Defibrillator (AED). The case features a breakable closed circuit that is, upon opening, triggered to send a signal to notify emergency medical services (EMS) or predefined contacts of the kit's location.The system utilizes GPS module and may include dual-mode communication capabilities for reliable alert transmission in various environments. Additional features may include a transparent case material for visual confirmation of contents, tamper-evident seals, QR codes linked to instructional content, and a battery power source. The kit is designed to be user-friendly, incorporating ergonomic elements and optional accessories for enhanced portability and storage, ensuring rapid and effective response in critical situations.

Methods and apparatuses for opioid overdose prevention are described. The apparatus comprises a memory and at least one processor coupled to the memory. The processor is configured to receive one or more measurements related to one or more vitals of a user, and cause, based on the one or more measurements, administration of a first dose of an overdose prevention medication to the user.

The application discloses application of a peripheral nervous system Mas-related G protein-coupled receptor D as a target point in preparation of a medicine for screening for relieving opioid tolerance. Jun The application further provides a medicine composition for regulating opioid tolerance, containing a Mas-related G protein-coupled receptor D siRNA sequence shown in SEQ ID NO. 1 or a siRNA sequence shown in SEQ ID NO. 2. The application further provides an in-situ hybridization kit for detecting expression of a Mas-related G protein-coupled receptor D gene in a dorsal root ganglion tissue of a peripheral nervous system. The application expands a new path for opioid companion diagnosis and intervention.

The invention discloses application of a peripheral nervous system Mas related G protein coupled receptor D as a target spot in preparing and screening a medicine for relieving opioid medicine tolerance. The invention also provides a pharmaceutical composition for regulating and controlling the tolerance of the opioid drugs. The pharmaceutical composition contains a Mas related G protein coupled receptor D siRNA sequence as shown in SEQ ID NO. 1 or a Jun siRNA sequence as shown in SEQ ID NO. 2. The invention also provides an in-situ hybridization kit for detecting the expression of the Mas related G protein coupled receptor D gene in the dorsal root ganglion tissue of the peripheral nervous system. According to the invention, a new path for accompanying diagnosis and intervention of opioid drugs is expanded.

To provide compounds and compositions for reducing most common opioid-induced hyperalgesia associated with microglial hyperactivation.SOLUTION: 2-pentadecyl-2-oxazoline (PEA-OXA) for use as an opioid adjuvant for preventing the development of or in the treatment of opioid-induced hyperalgesia (OIH), wherein the PEA-OXA is administered with or in combination with an opioid. Wherein the administration is separate, together or simultaneous.SELECTED DRAWING: None

Methods and compounds to therapeutically treat a molecular target to counteract circuit adaptations of long-term opioid use that are associated with a functional disability and negative affect in both CBP−O (chronic back pain managed without opioids) and CBP+O (chronic back pain managed with opioids).

A method, apparatus and computer program product are provided for a compiled standardized measure representative of a subset of prescription transactions associated with a controlled substance. The compiled standardized measures may be used in the prescription domain to notify prescribers of a patient's morphine milligram equivalent (MME) to reduce risks related to drug overdose, abuse, and the like. Historical prescription transactions may be accessed to identify prescriptions classified as an opioid or other controlled substance, and that may likely still be in a patient's possession based upon days supply, such that a daily MME may be calculated. Messaging is provided to the prescriber if the amount exceeds a maximum threshold, and the prescription can be changed accordingly.

2-Pentadecyl-2-oxazoline (also known as palmitoylethanolamide oxazoline or PEA-OXA) is used to counteract hyperalgesia induced by the most common opioids (OIH) associated with microglial hyperactivation. In particular, PEA-OXA is administered to humans and animals to prevent or treat some of the adverse effects of opioids by controlling immune hyperactivation. The PEA-OXA is administered separately, sequentially or jointly with the opioid.

The invention relates to the technical field of gene detection, in particular to an opioid analgesic drug gene detection method based on multiple targeted amplification, which comprises the following steps: extracting DNA from a peripheral blood sample; the method comprises the following steps: setting a primer pool aiming at a preset site of a specific gene related to opioid drugs, and carrying out multi-targeted amplification sequencing by using the primer pool to obtain sequencing data; comparing the sequencing data with a human reference genome to obtain a data comparison rate, and judging the eligibility of the multi-target amplification sequencing process according to the data comparison rate; performing variation detection on the qualified sequencing data, identifying the base type of each SNP site, and determining the genotype of the subject in combination with a dbSNP database; and inputting the genotype and clinical data into a pre-trained multi-gene prediction model, and obtaining the medication guidance of the subject for using the opioid drugs. The gene detection efficiency is improved.

The present invention relates to a pharmaceutical composition for treating drug addiction comprising opioid receptor nanodiscs and to a method for preparing opioid receptor nanodiscs. Specifically, the opioid receptor nanodiscs, according to the present invention, inhibit the interaction between an opioid receptor and an opioid-based drug without exhibiting toxicity in the body, are delivered to the brain when administered into the body, and significantly restore the delay in a hot-plate response caused by opioid-based drug addiction, thereby being usefully applicable to treatment of opioid-based drug addiction.

Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.

A novel and useful respiratory monitoring system and related methods that can interact with an opioid user and initiate a lifesaving drug injection process to mitigate opioid induced respiratory depression in an opioid user when opioid induced respiratory depression is detected. The system and methods include a wearable device that acquires physiological and other information from an opioid user during an opioid use session, analyzes the information to detect the presence of opioid induced respiratory depression in the opioid user, and initiates a lifesaving drug injection process when the presence of opioid induced respiratory depression is detected. Several methods are disclosed including self-monitoring and remote monitoring schemes that present a challenge to the opioid user with post injection stimulation of the opioid user and notification of caregivers and medical personnel.

The present disclosure provides methods and compositions for reducing the addictive liability of opioid analgesics in a subject, for example, by co-administering to the subject the opioid and a serotonin receptor type 2 (5HT2) agonist or a serotonin (5HT) releasing agent. The disclosed methods include methods for preventing opioid abuse, methods for reducing the rewarding effect of an opioid, methods for reducing the addictive liability of an opioid, methods for eliminating or substantially reducing the tendency for a subject to develop physical dependence, tolerance, and / or withdrawal symptoms with respect to an opioid, and methods for eliminating or substantially reducing the tendency for a subject to use opioids in ways not prescribed, take opioids more often or in larger amounts than prescribed, and / or use opioids recreationally. The methods can be performed on a subject, such as a patient (e.g., a human patient).

Naloxone variants that are both long lasting and responsive are disclosed. One version of the compound has a boron ester functional group and the antagonist compound is capable of a sustained release of antagonist based on reaction with hydrogen peroxide. In addition, a method of treating opioid overdose is disclosed. The method involves administering a therapeutically effective amount of the formulation described above to a patient in need thereof. Administration occurs either intranasally, sublingually or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly.

The invention relates to a multi-channel up-conversion nano-biosensing system and a method for detecting the content of opioid drugs by using the multi-channel up-conversion nano-biosensing system. According to the technical scheme, the preparation method comprises the following steps: S1, synthesizing up-conversion nanoparticles; the up-conversion nanoparticles are one of red light nanoparticles, blue light nanoparticles and green light nanoparticles; s2, carrying out surface functionalization on the up-conversion nanoparticles; s3, selection and modification of an aptamer; the invention provides an upconversion aptamer sensor capable of simultaneously detecting three opioid drugs.

This invention relates to the field of traditional Chinese medicine preparation technology, and particularly to a traditional Chinese medicine composition for treating cancer pain and numbness, as well as its preparation and application. This invention designs a traditional Chinese medicine composition for cancer pain and numbness, comprising: *Houttuynia cordata*, *Aconitum carmichaelii*, processed *Aconitum carmichaelii*, centipede, *Astragalus membranaceus*, *Ephedra sinica*, clove, frankincense, ephedra, menthol, and azone. The scientifically formulated combination of principal, assistant, and adjuvant herbs allows for multi-target action on both "cancer pain" (inflammation, compression, nerve infiltration) and "CIPN" (nerve damage), resulting in a superior analgesic effect, while also possessing anti-inflammatory, anti-swelling, potential tumor-suppressing, and nerve-repairing effects. The traditional Chinese medicine composition is prepared into a traditional Chinese medicine ointment, which is administered transdermally, allowing a high concentration of the drug to act directly on the lesion, avoiding the systemic side effects (addiction, constipation, etc.) associated with oral opioids. This is especially suitable for patients who cannot take oral opioids or cannot tolerate them.

Nicotine delivery devices and systems, particularly smoking cessation systems are provided by the present disclosure. Such devices and systems produce a nicotine-containing aerosol for inhalation that mimics smoking. The devices are capable of being adapted to control the amount of nicotine delivered to taper the amount of nicotine delivered to the user over time. Methods for treating patients to stop smoking are also disclosed. The devices, systems and methods can also be used to deliver other drugs disclosed herein, such as opioids (e.g., fentanyl).

A substance detector includes curcumin and is safe for human handling. The curcumin, as part of a wetting agent of the substance detector, changes color on contact with opioids and related illicit substances. A corresponding method detects very small quantities of an opioid via a rapid color change on a wet wipe when contacted with the opioid. Because the color change takes place on the wet wipe relatively quickly, there is no need to mix reagents to produce a color change reaction.

Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. In some embodiments, methods include hydrating the subject, such as by administering a hydration fluid composition to the subject. Methods according to certain embodiments may also include co-administering an opioid to the subject. Also provided is a transdermal delivery device configured to deliver dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery device.

Problem The purpose of the present invention is to provide a novel method for prevention and / or treatment of opioid tolerance or opioid dependence. Specifically, the purpose of the present invention is to develop peptide-based blockers to block MOR-DOR and KOR-DOR heterodimerization. In addition, the purpose of the present invention is to develop homodimer blockers for MOR, DOR, and KOR which modulate their downstream signaling without affecting their internalization. Solution The present invention is a prophylactic and / or therapeutic agent for the prevention and / or treatment of opioid tolerance or opioid dependence comprising the peptide which inhibits the dimer formation of the opioid receptor, wherein the above opioid receptor dimer is a heterodimer or a homodimer formed from one or two opioid receptors selected from the group consisting of the μ type (MOR), the κ type (KOR), and the δ type (DOR).

A novel and useful respiratory monitoring system and related methods that can interact with an opioid user and initiate a lifesaving drug injection process to mitigate opioid induced respiratory depression in an opioid user when opioid induced respiratory depression is detected. The system and methods include a wearable device that acquires physiological and other information from an opioid user during an opioid use session, analyzes the information to detect the presence of opioid induced respiratory depression in the opioid user, and initiates a lifesaving drug injection process when the presence of opioid induced respiratory depression is detected. Several methods are disclosed including self-monitoring and remote monitoring schemes that present a challenge to the opioid user with post injection stimulation of the opioid user and notification of caregivers and medical personnel.

A novel and useful respiratory monitoring system and related methods that can interact with an opioid user and initiate a lifesaving drug injection process to mitigate opioid induced respiratory depression in an opioid user when opioid induced respiratory depression is detected. The system and methods include a wearable device that acquires physiological and other information from an opioid user during an opioid use session, analyzes the information to detect the presence of opioid induced respiratory depression in the opioid user, and initiates a lifesaving drug injection process when the presence of opioid induced respiratory depression is detected. Several methods are disclosed including self-monitoring and remote monitoring schemes that present a challenge to the opioid user with post injection stimulation of the opioid user and notification of caregivers and medical personnel.

The invention relates to the technical field of medicines, and particularly discloses application of 9-anthraformic acid in preparation of a non-addictive peripheral analgesic medicine. It is proved for the first time that 9-anthracene formic acid has a remarkable analgesic effect and can effectively relieve inflammatory pain, the action target is a peripheral part, central side effects such as addiction and respiratory depression of traditional opioid analgesic are avoided, gastrointestinal injury, cardiovascular risk and curative effect capping effect of non-steroidal anti-inflammatory drugs are also overcome, and the 9-anthracene formic acid can be applied to preparation of anti-inflammatory drugs. Animal experiments prove that the analgesic effect of the compound is comparable with that of classical opioid drug morphine, and a brand new candidate drug and an application direction are provided for developing novel non-addiction analgesic drugs.

Compounds having opioid characteristics are provided that can be used for various therapeutic methods including the treatment of pain and opioid use disorders, and compounds having opioid antagonist properties that can be used to treat opioid overdoses. These compounds include agonists and antagonists having selective activity toward more one or more opioid receptors. Such compounds can be full or partial agonists, or can be antagonists lacking agonist properties toward delta and kappa opioid receptors. The partial agonists can diminish side effects associated with traditional opioid medications, and the antagonists can overcome respiratory depression caused by potent narcotics. Structurally these compounds include constrained piperidines with alkenyl or cyanoalkyl groups, as well as other substituents providing desired properties.

A glove and method of detecting a toxic substance on a surface is disclosed. A coating is applied over an exterior surface of at least a portion of the glove. The coating is formulated to detect toxic substances when the glove is donned and brought into contact with an object or surface. In particular, the coating may be formulated to detect toxic substances such as opioids and drug mixtures which include opioids. The coating may be applied over substantially the entire exterior surface of the glove or as coated regions formed on the palm region and / or digit regions of the glove. When the glove is brought into direct physical contact with the toxic substance it is formulated to detect, at least one characteristic of the coating changes. In some instances, the coating will change color when the toxic substance is contacted.

Tamper-resistant pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.

Opioids can be detected using a test system with ZnO pillars arranged in an array on a silicon wafer. Silver particles are on a top surface and / or side surface of the ZnO pillars. A sample fluid is applied to the test system. A concentration of an opioid compound in the sample fluid is determined using Surface-Enhanced Raman Spectroscopy of the test system. The sample fluid can be blood or a fluid isolated from blood.

Aspects of the present invention are directed to structurally modified opioids (SMOs) that result in improved modulating activity at the NMDAR and improved PK and PD parameters over existing drugs with NMDAR modulating activity. The structural modifications of an opioid or opioid enantiomer that result in the SMOs can be obtained by starting the synthetic process de novo; by modifying the synthetic process for the opioid at any intermediate step during the synthesis of the racemate or of one enantiomer; or by modifying the structure of the opioid or opioid enantiomer after the synthesis. The nitric acid ester substitutions are of particular relevance, especially when associated to deuterated substitutions and / or halogen substitutions.

The invention belongs to the technical field of biological medicine, and relates to a peptide protein kinase C inhibitor and application thereof, in particular to a protein kinase C zeta type novel inhibitor and application thereof as a tissue penetrating agent, especially in the background of cancer prevention and / or treatment or immune response induction, especially mucosal vaccination or anti-opioid drug treatment. The inhibitors are peptides having a total of 5 to 10 amino acids of the structure of formula (I), advantageously useful for inducing transient tissue penetration, in particular for enhancing penetration of large therapeutic molecules, for transmucosal delivery of high molecular weight drugs, avoiding parenteral administration of such drugs.